Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside DOI Open Access
Urna Kansakar, Crystal Nieves Garcia,

Gaetano Santulli

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7391 - 7391

Опубликована: Дек. 4, 2024

Ketone bodies are molecules produced from fatty acids in the liver that act as energy carriers to peripheral tissues when glucose levels low. Carbohydrate- and calorie-restricted diets, known increase of circulating ketone bodies, have attracted significant attention recent years due their potential health benefits several diseases. Specifically, increasing ketones through dietary modulation has been reported be beneficial for cardiovascular improve homeostasis insulin resistance. Interestingly, although excessive production may lead life-threatening ketoacidosis diabetic patients, mounting evidence suggests modest play adaptive roles pancreatic beta cells, exact mechanisms still unknown. Of note, Sodium-Glucose Transporter 2 (SGLT2) inhibitors shown beta-hydroxybutyrate (BHB), most abundant human body, which a pivotal role mediating some protective effects diabetes. This systematic review provides comprehensive overview scientific literature presents an analysis on pathophysiology cell function. The both preclinical clinical studies indicates exogenous cardiomyocytes making them intriguing candidates cardioprotective therapies preserve function patients with

Язык: Английский

Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis DOI Open Access
Attila Nagy, Ágnes Tóth,

Narin Bak

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7093 - 7093

Опубликована: Ноя. 24, 2024

: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, initially designed for type diabetes, promote glucose excretion and lower blood glucose. Newer analogs like empagliflozin dapagliflozin improve cardiovascular outcomes through mechanisms other than glycemic control, including pressure reduction anti-inflammatory effects. Given the high risk present in our study aims to emphasize cardioprotective benefits of SGLT-2 inhibitors as a preventive therapy heart failure (HF) high-risk T2DM patients.

Язык: Английский

Процитировано

0
Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside DOI Open Access
Urna Kansakar, Crystal Nieves Garcia,

Gaetano Santulli

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7391 - 7391

Опубликована: Дек. 4, 2024

Ketone bodies are molecules produced from fatty acids in the liver that act as energy carriers to peripheral tissues when glucose levels low. Carbohydrate- and calorie-restricted diets, known increase of circulating ketone bodies, have attracted significant attention recent years due their potential health benefits several diseases. Specifically, increasing ketones through dietary modulation has been reported be beneficial for cardiovascular improve homeostasis insulin resistance. Interestingly, although excessive production may lead life-threatening ketoacidosis diabetic patients, mounting evidence suggests modest play adaptive roles pancreatic beta cells, exact mechanisms still unknown. Of note, Sodium-Glucose Transporter 2 (SGLT2) inhibitors shown beta-hydroxybutyrate (BHB), most abundant human body, which a pivotal role mediating some protective effects diabetes. This systematic review provides comprehensive overview scientific literature presents an analysis on pathophysiology cell function. The both preclinical clinical studies indicates exogenous cardiomyocytes making them intriguing candidates cardioprotective therapies preserve function patients with

Язык: Английский

Процитировано

0